EpicentRx Receives Fast Track Designation from the U.S. FDA for Lead Asset, RRx-001

epicentrx.com/2023/epicentr...

About RRx-001

RRx-001 is a highly selective NLRP3 inhibitor under investigation in a Phase 3 trial for the treatment of small cell lung cancer (SCLC), and a planned Phase 2b trial for protection against oral mucositis in first line head and neck cancer. It is also under development as a medical countermeasure for nuclear and radiological emergencies and as a treatment for neurodegenerative diseases like Parkinson’s and ALS/MND.

Also related

A grant from

@MichaelJFoxOrg

will support research on the therapeutic potential of RRx-001, EpicentRx's first-in-class inflammasome inhibitor, in Parkinson's disease. The program will be led by

@Gordon_NeuroLab

in Brisbane, Australia. ow.ly/3Ok950JTZQj

[Boscoejean]

michaeljfox.org/grant/valid...